NCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
Clinical Trials
10 trialsNCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT03802747 2024-12-09
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
University of Colorado, Denver
Phase 1 Withdrawn
NCT05120622 2023-10-31
Rideau
University of British Columbia
Phase 1/2 Withdrawn
NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT03319316 2022-01-10
SOLUTION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT04223648 2021-11-22
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Yale University
Phase EARLY_PHASE1 Withdrawn
NCT04073160 2020-07-07
TRIO Bladder
Duke University
Phase 1 Withdrawn
NCT00880854 2019-11-15
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
University of Wisconsin, Madison
Phase 1 Withdrawn
NCT02868632 2019-04-05
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
NYU Langone Health
Phase 1 Withdrawn